Abstract: Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

Abstract: Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

Abstract: The present invention provides methods embodied in a system that can be applied to genetic information comprising an individual genome to assess the regulatory impact of specific genetic variants and their possible impact on biological function or disease pathology.

Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Abstract: Embodiments of the present invention provide diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on a combination of such markers obtained from various analyzes, primarily from blood, testing immune function including the analysis of immune cell subset frequencies, gene expression, cytokine and chemokine levels, and signaling responses to stimulation with cytokines (‘cytokine response’). Particular combinations of markers can predict with high accuracy whether an individual will respond to active vaccination and become protected against recurring diseases.

Abstract: Methods of treatment for melanoma, and compositions for use in such methods are provided. An effective dose of an agent that blocks benzamil-sensitive proteins is administered to an individual suffering from melanoma.

Abstract: Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

Abstract: Methods of modulating lung cancer, e.g., squamous cell carcinoma (SQCC), tumor initiating cells (TIC) are provided. Aspects of the methods including contacting a TIC with an OXTR modulatory agent, e.g., an inhibitory agent, in a manner sufficient to modulate the TIC. Aspects of the invention further include compositions that find use in practicing methods of the method. The methods and compositions find use in a variety of different applications, including but not limited to the treatment of SQCC.

Abstract: Methods of treatment for psoriasis, and compositions for use in such methods are provided. An effective dose of an epithelial ion channel (ENAC) blocker is administered to an individual suffering from psoriasis. ENAC blockers, including without limitation Benzamil, can reduce thickened cutaneous psoriatic plaques.

Abstract: Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

Abstract: Biomarkers and biomarker panels are provided for making ovarian cancer assessments, for example, diagnosing an ovarian cancer, predicting responsiveness of an ovarian cancer to an ovarian cancer therapy, and monitoring an ovarian cancer. A patient may further be treated in accordance with the classification. Also provided are methods, reagents, devices and kits for the use of these biomarkers in making ovarian cancer assessments.

Abstract: An embodiment of the present invention is a methodology for prioritizing variants relevant to inherited Mendelian (“single gene”) disease syndromes according to disease phenotype, gene, and variant level information.

Abstract: Preeclampsia peptide biomarkers are provided. Also provided are methods for using these biomarkers, including in prognosing or diagnosing preeclampsia in a pregnant individual by detecting these biomarkers in a sample from the pregnant individual. Reagents, devices and kits thereof that find use in practicing the subject methods are also provided.

Abstract: Methods for identifying new therapeutic activities for known therapeutic agents, as well as systems for practicing the same, are provided. Aspects of the invention further include are methods and compositions for the treatment of an acute graft rejection (AR).

Abstract: Preeclampsia markers, preeclampsia marker panels, and methods for obtaining a preeclampsia marker level representation for a sample are provided. These compositions and methods find use in a number of applications, including, for example, diagnosing preeclampsia, prognosing a preeclampsia, monitoring a subject with preeclampsia, and determining a treatment for preeclampsia. In addition, systems, devices and kits thereof that find use in practicing the subject methods are provided.

Abstract: Methods and systems are provided for the computation and display of an individual's personalized health risk based on the genome sequence of the individual, known etiological interactions between diseases for which the individual is determined to have genetic risk factors, and environmental etiological factors associated with the same diseases that represent potentially modifiable disease risk modifiers.

Abstract: An embodiment of the present invention uses logistic regression models that correlate post-marketing ADRs with screening data from the PubChem BioAssay database. These models of the present invention analyze ADRs at the level of organ systems, the System Organ Classes (SOCs). In testing to evaluate an embodiment of the present invention, nine of 19 SOCs under consideration were found to be significantly correlated with pre-clinical screening data. For six of eight established drugs for which SOC-specific adversities could be retropredicted, prior knowledge was found that support these predictions. SOC-specific adversities were then predicted for three unapproved or recently introduced drugs.

Abstract: Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Abstract: Embodiments of the present invention provide methods and systems that perform comprehensive assessment of genetic variation presenting in a personal genome and provide quantitative diagnosis of the impact of each variant on physiological function and patient health.